Fusion Antibodies: against COVID-19 Company
Entity: Fusion Antibodies
Category: Vaccine Development
Description: Fusion Antibodies specializes in producing humanized monoclonal antibodies and antibody engineering projects. The company has the knowledge and expertise to build and deliver a bespoke package of the services people need to achieve outstanding results. Using the technology, the sequences of the antibody variable domains which determine its binding specificity are incorporated into human donor sequences creating a panel of full length humanized antibodies for expression. Fully humanized monoclonal antibodies are an essential step in the progression of your drug to the clinic and the in-house expertise at Fusion Antibodies ensures its success. All of Fusion Antibodies services are offered on a fee-for-service basis and is flexible on the elements of the project people would like included. Fusion Antibodies have strong links with the several partners around the globe, allowing it to deliver a complete bespoke package, at an incredible price.
Project: New antibody tools
Summary: An alliance between Queen’s researchers and the leading local biotech company, Fusion Antibodies, is using the latest technologies to develop new antibody tools to both help detect and neutralise SARS-CoV-2.
+ Investors:
Clarendon Fund Managers
Crescent Capital
QUBIS
+ Government Funders:
Invest Northern Ireland
